Fan Wei

bioAffinity Technologies Executes Agreement with Fosun Long March to Evaluate CyPath® Lung for Commercialization in China

Retrieved on: 
Thursday, February 4, 2021
Science, Biotechnology, Research, Pharmaceutical, Surgery, Oncology, Health, Medical devices, Companies of China, Companies, Fosun International, Economy of China, Fosun Pharma, Fan Wei, Fosun Long March, bioAffinity Technologies, Inc.

Shanghai Fosun Long March Medical Science Co., Ltd. (Fosun Long March) has executed a non-binding Letter of Intent (LOI) with bioAffinity Technologies, Inc. providing for Fosun to evaluate CyPath Lung, a non-invasive test for the early detection of lung cancer, with an expectation of negotiating and entering into binding agreements to commercialize the early lung cancer diagnostic in China.

Key Points: 
  • Shanghai Fosun Long March Medical Science Co., Ltd. (Fosun Long March) has executed a non-binding Letter of Intent (LOI) with bioAffinity Technologies, Inc. providing for Fosun to evaluate CyPath Lung, a non-invasive test for the early detection of lung cancer, with an expectation of negotiating and entering into binding agreements to commercialize the early lung cancer diagnostic in China.
  • Fosun Long March is a wholly owned company of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ( Fosun Pharma , stock code: 02196.HK; 600196.SH).
  • We look forward to proceeding with the collaboration with bioAffinity Technologies and working together to launch CyPath Lung in China.
  • We are very excited to be working with Fosun Long March in advancing CyPath Lung.

MimiVax LLC and Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. announce exclusive licensing agreement on SurVaxM for glioblastoma treatment in China

Retrieved on: 
Monday, November 18, 2019
Companies of China, Companies, Fosun International, Economy of China, H shares, Fosun Pharmaceutical, Sun Pharmaceutical, Fan Wei

BUFFALO, N.Y. and SHANGHAI, Nov. 18, 2019 /PRNewswire/ -- MimiVax LLC and Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (Fosun Pharma Industrial) today announced the companies have entered into a China-exclusive licensing agreement for SurVaxM, a novel anti-cancer immunotherapy in the treatment of glioblastoma brain cancers.

Key Points: 
  • BUFFALO, N.Y. and SHANGHAI, Nov. 18, 2019 /PRNewswire/ -- MimiVax LLC and Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (Fosun Pharma Industrial) today announced the companies have entered into a China-exclusive licensing agreement for SurVaxM, a novel anti-cancer immunotherapy in the treatment of glioblastoma brain cancers.
  • Fosun Pharma Industrial is a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co. Ltd (Fosun Pharma), a leading healthcare group in China with extensive healthcare business interests worldwide.
  • Fosun Pharma will work with MimiVax on the clinical, regulatory and commercial pathways necessary to bring SurVaxM to China.
  • Established in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"; stock code: 600196.SH, 02196.HK) is a leading healthcare group in the PRC.